Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Oruka Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 16 filings
- 6 insiders, $319.8M in total
- Insiders trading
- 6
- Net value
- −$319.8M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Oruka Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Agarwal Arjun | Senior Vice President, Finance | 14,219 | Sep 21, 2026 | 9 |
| Quinlan Paul T | General Counsel | 29,995 | Sep 21, 2026 | 6 |
| Goncalves Joana | Chief Medical Officer | 31,771 | Sep 15, 2026 | 11 |
| Klein Lawrence Otto | Chief Executive Officer | 923,128 | Sep 15, 2026 | 5 |
| Sandler Laura Lee | Chief Operating Officer | 235,478 | Sep 15, 2026 | 9 |
| Edwards Larry Todd | Chief Commercial Officer | 100,000 | Aug 25, 2026 | 1 |
| Harwin Peter Evan | Director, 10% Owner | 1,131,954Indirect | Jul 1, 2026 | 2 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Owner | 1,131,954Indirect | Jul 1, 2026 | 2 |
| Fairmount Funds Management LLC | Director, 10% Owner | 1,131,954Indirect | Jul 1, 2026 | 2 |
| Kiselak Tomas | Director, 10% Owner | 1,131,954Indirect | Jul 1, 2026 | 2 |
| Fairmount Healthcare Co-Invest III L.P. | Director, 10% Owner | 1,131,954Indirect | Jul 1, 2026 | 2 |
| Dambkowski Carl | Director | 38,743 | Jun 12, 2026 | 4 |
| Ball Kristine M | Director | – | Jun 3, 2026 | 1 |
| Kulkarni Samarth | Director | – | Jun 3, 2026 | 1 |
| Martin Christopher Nathan | Director | – | Jun 3, 2026 | 2 |
| Turtle Cameron | Director | – | Jun 3, 2025 | 0 |
| Koh Bong Y | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| Shah Nimish P | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| Venrock Healthcare Capital Partners III, L.P. | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| VHCP Management III, LLC | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| VHCP Co-Investment Holdings III, LLC | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| Venrock Healthcare Capital Partners EG, L.P. | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| VHCP Management EG, LLC | 10% Owner | 4,148,428Indirect | Feb 27, 2025 | 0 |
| Ma-Weaver Jacob | Other: See footnote 1 | 4,000,452 | Aug 30, 2024 | 0 |
| Janus Henderson Group PLC | 10% Owner | 2,117,213Indirect | Aug 20, 2024 | 0 |
| Janus Henderson Biotech Innovation Master Fund Ltd | 10% Owner | 2,117,213Indirect | Aug 20, 2024 | 0 |
| Mitchell Daniel J | Director | – | Jan 31, 2024 | 0 |
| Conway Robert E | Director, Other: Chairman of the Board | – | Jan 31, 2024 | 0 |
| Hove Anders D | Director | – | Jan 31, 2024 | 0 |
| Grais Linda | Director | – | Jan 31, 2024 | 0 |
| Woosley Raymond L. | Director | – | Jan 31, 2024 | 0 |
| Flynn James P | Director | – | Jan 31, 2024 | 0 |
| Funicular Funds, LP | 10% Owner, Other: See Footnote 1 | 4,000,452 | Dec 19, 2022 | 0 |
| Keuer Thomas A | Chief Operating Officer | 40,730 | Dec 9, 2022 | 0 |
| Dekker C. Jeffrey | Chief Financial Officer | 40,000 | Dec 9, 2022 | 0 |
| Funicular Fund, LP | Other: See Footnote 1 | 2,580,452 | May 25, 2022 | 0 |
| Bristow Michael R | Pres. & Chief Executive Offic | – | Dec 16, 2021 | 0 |
| Ozeroff Christopher David | S.V.P., General Counsel | 50,970 | Dec 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)6:36 PM ET | Sep 1 | Same day | Sandler Laura LeeChief Operating Officer | SSale | −5.00K | $91.82 | −$459.1K | −2.1%236.4K after | 2 lots10b5-1 |
| Sep 15, 2026 (view filing)7:11 PM ET | Sep 15 | Same day | Sandler Laura LeeChief Operating Officer | SSale | −906 | $95.71 | −$86.7K | −0.4%235.5K after | |
| Sep 15, 2026 (view filing)7:14 PM ET | Sep 15 | Same day | Quinlan Paul TGeneral Counsel | SSale | −1.04K | $95.71 | −$99.4K | −3.3%30.0K after | |
| Sep 15, 2026 (view filing)7:15 PM ET | Sep 15 | Same day | Klein Lawrence OttoChief Executive Officer | SSale | −2.45K | $95.71 | −$234.7K | −0.3%923.1K after | |
| Sep 15, 2026 (view filing)7:17 PM ET | Sep 11-15 | 4 days | Agarwal ArjunSenior Vice President, Finance | SSale | −10.0K | $92.43 | −$926.0K | −40.4%14.8K after | 5 lots10b5-1 |
| Sep 15, 2026 (view filing)7:18 PM ET | Sep 15 | Same day | Goncalves JoanaChief Medical Officer | SSale | −7.95K | $92.38 | −$734.1K | −20.0%31.8K after | 5 lots10b5-1 |
| Sep 21, 2026 (view filing)4:57 PM ET | Sep 21 | Same day | Quinlan Paul TGeneral Counsel | SSale | −10.0K | $93.64 | −$936.4K | −25.0%30.0K after | 4 lots10b5-1 |
| Sep 21, 2026 (view filing)5:38 PM ET | Sep 21 | Same day | Agarwal ArjunSenior Vice President, Finance | SSale | −533 | $95.75 | −$51.0K | −3.6%14.2K after | 10b5-1 |